Sotorasib plus panitumumab versus standard-of-care for chemorefractory KRAS G12C-mutated metastatic colorectal cancer (mCRC): CodeBreak 300 phase III study

被引：1
|
作者：
Kuboki, Y. [1 ]
Pietrantonio, F. [2 ]
Salvatore, L. [3 ]
Esaki, T. [4 ]
Modest, D. P. [5 ]
Paez, D. [6 ]
Taieb, J. [7 ]
Ruiz, E. [8 ,9 ]
Kim, T. W. [10 ]
Meriggi, F. A. [11 ]
Cunningham, D. [12 ,13 ]
Yeh, K-H. [14 ]
Chan, E. [15 ]
Chao, J. [16 ]
Strydom, N. [17 ]
Saportas, Y. [18 ]
Tran, Q. [19 ]
Cremolini, C. [20 ]
Fakih, M. [21 ]
机构：
[1] Natl Canc Ctr Hosp East, Expt Therapeut & GI Oncol Dept, Kashiwa, Chiba, Japan
[2] Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol, Milan, Italy
[3] Fdn Policlin Univ Agostino Gemelli IRCC, Dipartimento Oncol, Rome, Italy
[4] Natl Hosp Org, Med Oncol, Kyushu Canc Ctr, Fukuoka, Japan
[5] Charite Univ Med Berlin, Dept Med Hematol Oncol & Tumorimmunol, Berlin, Germany
[6] Hosp Santa Creu & Sant Pau, Dept Med Oncol, Barcelona, Spain
[7] Hop European George Pompidou, Gastroenterol & Digest Oncol Dept, Paris, France
[8] INCAN Inst Nacl Cancerol, GI Oncol Dept, Ciudad De Mexico, Mexico
[9] INCAN Inst Nacl Cancerol, Translat Med Lab, Ciudad De Mexico, Mexico
[10] Univ Ulsan, Asan Med Ctr, Coll Med, Oncol Dept, Seoul, South Korea
[11] Fdn Poliambulanza Ist Osped, Oncol Dept, Brescia, Italy
[12] Inst Canc Res, Med Dept, Sutton, Surrey, England
[13] Royal Marsden Hosp, Sutton, Surrey, England
[14] NTUH Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan
[15] Amgen Inc, Global Dev, Thousand Oaks, CA USA
[16] Amgen USA, Oncol Therapeut Area, Seattle, WA USA
[17] Amgen Inc SSF, Clin Pharmacol, San Francisco, CA USA
[18] Amgen Headquarters USA, Global Safety, Thousand Oaks, CA USA
[19] Amgen Headquarters USA, Biostat, Thousand Oaks, CA USA
[20] AOU Pisana Stabilimento Santa Chiara, Polo Oncol, Pisa, Italy
[21] City Hope Comprehens Canc Ctr, Med Oncol Therapeut Res, Duarte, CA USA
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.10.226
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
91MO
引用
收藏
页码：S1504 / S1505
页数：2
相关论文
共 50 条
  • [31] Sotorasib versus docetaxel for previously treated KRAS G12C-mutated non-small-cell lung cancer: a plain language summary
    de Langen, Adrianus Johannes
    Johnson, Melissa L.
    Mazieres, Julien
    Dingemans, Anne-Marie C.
    Mountzios, Giannis
    Pless, Miklos
    Wolf, Juergen
    Schuler, Martin
    Lena, Herve
    Skoulidis, Ferdinandos
    Yoneshima, Yasuto
    Kim, Sang-We
    Linardou, Helena
    Novello, Silvia
    van der Wekken, Anthonie J.
    Chen, Yuanbin
    Peters, Solange
    Felip, Enriqueta
    Solomon, Benjamin J.
    Ramalingam, Suresh S.
    Dooms, Christophe
    Lindsay, Colin R.
    Ferreira, Carlos Gil
    Blais, Normand
    Obiozor, Cynthia C.
    Wang, Yang
    Mehta, Bhakti
    Varrieur, Tracy
    Ngarmchamnanrith, Gataree
    Stollenwerk, Bjoern
    Waterhouse, David
    Paz-Ares, Luis
    FUTURE ONCOLOGY, 2025,
  • [32] Health-related quality of life (HRQoL) in patients with metastatic colorectal cancer (mCRC) treated with sotorasib and panitumumab (pmab) versus trifluridine/tipiracil (T/T) or regorafenib (rego) in CodeBreaK 300.
    Modest, Dominik Paul
    Fakih, Marwan
    Salvatore, Lisa
    Esaki, Taito
    Lopez-Bravo, David Paez
    Taieb, Julien
    Karamouzis, Michalis
    Ruiz-Garcia, Erika
    Kim, Tae Won
    Kuboki, Yasutoshi
    Meriggi, Fausto
    Cunningham, David
    Yeh, Kun-Huei
    Cremolini, Chiara
    Tran, Qui
    Chan, Emily
    Chao, Joseph
    Majer, Istvan Matyas
    Pietrantonio, Filippo
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 10 - 10
  • [33] Efficacy of Sotorasib Versus Standard Chemotherapy plus Immunotherapy in KRAS G12C Mutated Lung Cancer: A Comparative Study Modeling Real-World Data
    Haddad, P.
    Hammoud, D.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (03) : E28 - E28
  • [34] A phase Ib/II study of sotorasib combined with chemotherapy for second-line treatment of KRAS p. G12C-mutated advanced pancreatic cancer
    Mahalingam, Devalingam
    Burns, Michael Charles
    Kalyan, Aparna
    Kircher, Sheetal Mehta
    Kocherginsky, Masha
    Mulcahy, Mary Frances
    Benson, Al Bowen
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [35] Safety and efficacy of D-1553 in KRAS G12C-mutated colorectal cancer: Results from a phase I/II study
    Ruan, Dan-yun
    Lee, Myung Ah
    Deng, Yanhong
    Lee, Keun-Wook
    Millward, Michael
    Grewal, Jaspreet Singh
    Gadgeel, Shirish M.
    Sanborn, Rachel E.
    Hou, Xinfang
    Wei, Shaozhong
    Huh, Seok Jae
    Liu, Fu-Rong
    Xie, Xiaoxi
    Xiang, Ziyong
    Shi, Zhe
    Wang, Yaolin
    Zhang, Ling
    Richardson, Gary Edward
    Xu, Rui-Hua
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [36] Analysis of KRAS/NRAS and BRAF mutations in the phase III PRIME study of panitumumab (pmab) plus FOLFOX versus FOLFOX as first-line treatment (tx) for metastatic colorectal cancer (mCRC).
    Oliner, Kelly S.
    Douillard, Jean-Yves
    Siena, Salvatore
    Tabernero, Josep
    Burkes, Ronald L.
    Barugel, Mario Edmundo
    Humblet, Yves
    Bodoky, Gyorgy
    Cunningham, David
    Jassem, Jacek
    Rivera, Fernando
    Kocakova, Ilona
    Ruff, Paul
    Blasinska-Morawiec, Maria
    Smakal, Martin
    Williams, Richard Thomas
    Rong, Alan
    Wiezorek, Jeffrey S.
    Sidhu, Roger
    Patterson, Scott D.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [37] An open label, randomized phase III trial evaluating the treatment (tx) effects of panitumumab (pmab) plus best supportive care (BSC) versus BSC in chemorefractory wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC) and in WT RAS mCRC.
    Kim, Tae Won
    Elme, Anneli
    Kusic, Zvonko
    Park, Joon Oh
    Udrea, Anghel Adrian
    Kim, Sun Young
    Ahn, Joong Bae
    Valencia, Ricardo Villalobos
    Srinivasan, Krishnan
    Bilic, Ante
    Manojlovic, Nebojsa
    Dong, Jun
    Guan, Xuesong
    Lofton-Day, Catherine
    Jung, A. Scott
    Vrdoljak, Eduard
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [38] Phase II study of panitumumab with irinotecan for patients with KRAS wild-type metastatic colorectal cancer (MCRC) refractory to standard chemotherapy: A GERCOR study
    Chibaudel, B.
    Tournigand, C.
    Mabro, M.
    Bennamoun, M.
    Artru, P.
    Nguyen, S.
    Bachet, J.
    Aissat, N.
    Blons, H.
    Laurent-Puig, P.
    De Gramont, A.
    Andre, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [39] Phase II Study of Panitumumab With Irinotecan for Patients With KRas Wild-type Metastatic Colorectal Cancer (MCRC) Refractory to Standard Chemotherapy - a GERCor Study
    Andre, T.
    Chibaudel, B.
    Mabro, M.
    Bennamoun, M.
    Artru, P.
    Bachet, J. B.
    Hadengue, A.
    Blons, H.
    Laurent-Puig, P.
    de Gramont, A.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S435 - S435
  • [40] Evaluation of gene mutations beyond KRAS as predictive biomarkers of response to panitumumab in a randomized, phase III monotherapy study of metastatic colorectal cancer (mCRC).
    Oliner, K.
    Peeters, M.
    Siena, S.
    Van Cutsem, E.
    Huang, J.
    Humblet, Y.
    Van Laethem, J.
    Andre, T.
    Wiezorek, J. S.
    Patterson, S. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345